Published: Friday, June 20, 2025 · 5:00 AM | Updated: Friday, June 20, 2025 · 5:00 AM
📊 336 views
Jun 19, 2025 / 02:00PM GMT
Tim Dyer – Addex Therapeutics Ltd – Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Hello, everyone. I’d like to thank you all for attending our Q1 2025 financial results conference call. I’m here with Mikhail Kalinichev, our Head of Translational Science, who will provide an update on our R&D program.
I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today.
I will start this conference call by giving a quick overview of recent activities and achievements before reviewing our top line. I will then hand over to Misha who will review in more detail our mGluR5 negative allosteric modular program for brain injury recovery and our GABAB positive allosteric modulation preclinical program for cough. I will then review our Q1 2025 financial results. Following that, we will open the call for Q&A.
Moving on to the highlights. We
MORE IN INSIDE INVESTMENT NEWS
Lululemon stock Plunges 20%: A Portfolio Warning for Retail Investors
Published: Friday, September 4, 2026 · 9:21 AM
Broadcom’s AI Growth: Alpha Potential in Next-Gen Chips
Published: Thursday, September 3, 2026 · 12:35 AM
